SAN DIEGO (AP) _ Conatus Pharmaceuticals Inc. (CNAT) on Wednesday reported a loss of $9.1 million in its fourth quarter.
On a per-share basis, the San Diego-based company said it had a loss of 35 cents.
The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 32 cents per share.
The biotechnology company posted revenue of $799,000 in the period.
For the year, the company reported a loss of $29.7 million, or $1.31 per share. Revenue was reported as $799,000.
In the final minutes of trading on Wednesday, the company's shares hit $4.91. A year ago, they were trading at $1.90.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CNAT at https://www.zacks.com/ap/CNAT
Keywords: Conatus Pharmaceuticals, Earnings Report